Nebivolol Generis (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Generis, is a beta‑adrenergic blocker presented as an oral tablet for oral use. It is indicated for the management of high blood pressure and may be prescribed for certain cardiac conditions in adults.

GNH USA supplies Nebivolol Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑blocker used primarily in the cardiovascular therapeutic area. It helps control blood pressure and supports heart function.

- Hypertension: lowers systolic and diastolic blood pressure to target levels. - Heart failure with reduced ejection fraction: improves symptoms and may reduce mortality. - Left ventricular hypertrophy: attenuates cardiac remodeling associated with chronic pressure overload.

Nebivolol may cause a range of adverse reactions, from mild to serious. Monitoring and patient education are essential.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or general weakness. - Nausea or mild gastrointestinal upset. - Bradycardia: heart rate slower than normal. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to syncope. - Allergic reactions such as rash, pruritus, or angioedema. - Hepatic dysfunction or elevated liver enzymes. - Worsening of heart failure symptoms. - Depression or mood changes.

Before initiating Nebivolol, clinicians should assess several safety factors and advise patients accordingly.

- Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Heart rate assessment: avoid use in patients with baseline bradycardia. - Asthma or chronic obstructive pulmonary disease: use with caution due to potential bronchospasm. - Abrupt discontinuation: taper dose to prevent rebound hypertension. - Hepatic impairment: consider dose adjustment or close monitoring. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects. - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma concentrations. - Verapamil or diltiazem: may cause profound bradycardia or AV‑block.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate antihypertensive effect. - Diuretics: increase risk of orthostatic hypotension. - Antidiabetic agents: may mask hypoglycemia symptoms. - Calcium channel blockers (non‑verapamil): monitor for additive blood pressure lowering. - Antidepressants (e.g., SSRIs): observe for enhanced bradycardia.